Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Nov;83(9):1202–1208. doi: 10.1054/bjoc.2000.1431

A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1

R W Wilkinson 1,2, E L Ross 1,2, A E Lee-MacAry 2, R Laylor 2, J Burchell 3, J Taylor-Papadimitriou 3, D Snary 2
PMCID: PMC2363579  PMID: 11027434

Abstract

MUC1 is a membrane bound, polymorphic epithelial mucin expressed at the luminal surface of glandular epithelium. It is highly expressed in an underglycosylated form on carcinomas and metastatic lesions and is, therefore, a potential target for immunotherapy of cancer. The monoclonal antibody HMFG1 binds the linear core protein sequence, PDTR, contained within the immunodominant domain of the tandem repeat of MUC1. The efficacy of murine and humanized HMFG1 (Ab1) used as an anti-idiotypic vaccine was examined in mice transgenic for human MUC1 (MUC1.Tg) challenged with murine epithelial tumour cells transfected with human MUC1. Humoral idiotypic cascade through Ab2 and Ab3 antibodies was observed in MUC1.Tg mice following multiple antibody inoculations in the presence of adjuvant. Impaired tumour growth at day 35 and highest Ab3 levels were found in mice that had received mHMFG1 with RAS adjuvant. However, comparison of Ab3 levels in individual mice with tumour size in all treatment groups did not show a correlation between smaller tumours and increased levels of anti-idiotype antibody. This suggests that the anti-tumour effects of anti-idiotype vaccination are not solely related to the induction of idiotypic antibody cascades and probably involve other mechanisms. © 2000 Cancer Research Campaign

Keywords: immunotherapy, MUC1 transgenic mice, anti-idiotypic vaccines

Full Text

The Full Text of this article is available as a PDF (93.5 KB).

Footnotes

Authors contributed equally to the work

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agrawal B., Krantz M. J., Reddish M. A., Longenecker B. M. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med. 1998 Jan;4(1):43–49. doi: 10.1038/nm0198-043. [DOI] [PubMed] [Google Scholar]
  2. Apostolopoulos V., Xing P. X., Trapani J. A., McKenzie I. F. Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. Br J Cancer. 1993 Apr;67(4):713–720. doi: 10.1038/bjc.1993.131. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bona C. A. Idiotype vaccines: forgotten but not gone. Nat Med. 1998 Jun;4(6):668–669. doi: 10.1038/nm0698-668. [DOI] [PubMed] [Google Scholar]
  4. Boon T, Old LJ. Cancer Tumor antigens. Curr Opin Immunol. 1997 Oct 1;9(5):681–683. doi: 10.1016/s0952-7915(97)80049-0. [DOI] [PubMed] [Google Scholar]
  5. Boyle C. C., Paine A. J., Mather S. J. The mechanism of hepatic uptake of a radiolabelled monoclonal antibody. Int J Cancer. 1992 Apr 1;50(6):912–917. doi: 10.1002/ijc.2910500616. [DOI] [PubMed] [Google Scholar]
  6. Burchell J., Durbin H., Taylor-Papadimitriou J. Complexity of expression of antigenic determinants, recognized by monoclonal antibodies HMFG-1 and HMFG-2, in normal and malignant human mammary epithelial cells. J Immunol. 1983 Jul;131(1):508–513. [PubMed] [Google Scholar]
  7. Burchell J., Gendler S., Taylor-Papadimitriou J., Girling A., Lewis A., Millis R., Lamport D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987 Oct 15;47(20):5476–5482. [PubMed] [Google Scholar]
  8. Burchell J., Taylor-Papadimitriou J. Effect of modification of carbohydrate side chains on the reactivity of antibodies with core-protein epitopes of the MUC1 gene product. Epithelial Cell Biol. 1993 Oct;2(4):155–162. [PubMed] [Google Scholar]
  9. Daly T. M., Long C. A. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect Immun. 1996 Jul;64(7):2602–2608. doi: 10.1128/iai.64.7.2602-2608.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eades-Perner A. M., van der Putten H., Hirth A., Thompson J., Neumaier M., von Kleist S., Zimmermann W. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 1994 Aug 1;54(15):4169–4176. [PubMed] [Google Scholar]
  11. Foon K. A., John W. J., Chakraborty M., Sherratt A., Garrison J., Flett M., Bhattacharya-Chatterjee M. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. Clin Cancer Res. 1997 Aug;3(8):1267–1276. [PubMed] [Google Scholar]
  12. Foon K. A., Sen G., Hutchins L., Kashala O. L., Baral R., Banerjee M., Chakraborty M., Garrison J., Reisfeld R. A., Bhattacharya-Chatterjee M. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin Cancer Res. 1998 May;4(5):1117–1124. [PubMed] [Google Scholar]
  13. Garrido F., Cabrera T., Concha A., Glew S., Ruiz-Cabello F., Stern P. L. Natural history of HLA expression during tumour development. Immunol Today. 1993 Oct;14(10):491–499. doi: 10.1016/0167-5699(93)90264-L. [DOI] [PubMed] [Google Scholar]
  14. Gendler S. J., Burchell J. M., Duhig T., Lamport D., White R., Parker M., Taylor-Papadimitriou J. Cloning of partial cDNA encoding differentiation and tumor-associated mucin glycoproteins expressed by human mammary epithelium. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6060–6064. doi: 10.1073/pnas.84.17.6060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J Biol Chem. 1988 Sep 15;263(26):12820–12823. [PubMed] [Google Scholar]
  16. Graham R. A., Burchell J. M., Taylor-Papadimitriou J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother. 1996 Feb;42(2):71–80. doi: 10.1007/s002620050254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jerne N. K. Towards a network theory of the immune system. Ann Immunol (Paris) 1974 Jan;125C(1-2):373–389. [PubMed] [Google Scholar]
  18. Karsten U., Diotel C., Klich G., Paulsen H., Goletz S., Müller S., Hanisch F. G. Enhanced binding of antibodies to the DTR motif of MUC1 tandem repeat peptide is mediated by site-specific glycosylation. Cancer Res. 1998 Jun 15;58(12):2541–2549. [PubMed] [Google Scholar]
  19. Kosmas C., Kalofonos H. P., Hird V., Epenetos A. A. Monoclonal antibody targeting of ovarian carcinoma. Oncology. 1998 Sep-Oct;55(5):435–446. doi: 10.1159/000011892. [DOI] [PubMed] [Google Scholar]
  20. Lalani E. N., Berdichevsky F., Boshell M., Shearer M., Wilson D., Stauss H., Gendler S. J., Taylor-Papadimitriou J. Expression of the gene coding for a human mucin in mouse mammary tumor cells can affect their tumorigenicity. J Biol Chem. 1991 Aug 15;266(23):15420–15426. [PubMed] [Google Scholar]
  21. Miles D. W., Towlson K. E., Graham R., Reddish M., Longenecker B. M., Taylor-Papadimitriou J., Rubens R. D. A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. Br J Cancer. 1996 Oct;74(8):1292–1296. doi: 10.1038/bjc.1996.532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Miller F. R., Miller B. E., Heppner G. H. Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis. 1983;3(1):22–31. [PubMed] [Google Scholar]
  23. Peat N., Gendler S. J., Lalani N., Duhig T., Taylor-Papadimitriou J. Tissue-specific expression of a human polymorphic epithelial mucin (MUC1) in transgenic mice. Cancer Res. 1992 Apr 1;52(7):1954–1960. [PubMed] [Google Scholar]
  24. Pride M. W., Shuey S., Grillo-Lopez A., Braslawsky G., Ross M., Legha S. S., Eton O., Buzaid A., Ioannides C., Murray J. L. Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res. 1998 Oct;4(10):2363–2370. [PubMed] [Google Scholar]
  25. Raychaudhuri S., Tonks M., Carbone F., Ryskamp T., Morrow W. J., Hanna N. Induction of antigen-specific class I-restricted cytotoxic T cells by soluble proteins in vivo. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):8308–8312. doi: 10.1073/pnas.89.17.8308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Riethmüller G., Schneider-Gädicke E., Schlimok G., Schmiegel W., Raab R., Höffken K., Gruber R., Pichlmaier H., Hirche H., Pichlmayr R. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group. Lancet. 1994 May 14;343(8907):1177–1183. doi: 10.1016/s0140-6736(94)92398-1. [DOI] [PubMed] [Google Scholar]
  27. Rodolfo M., Melani C., Zilocchi C., Cappetti B., Luison E., Arioli I., Parenza M., Canevari S., Colombo M. P. IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but not IgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases. Cancer Res. 1998 Dec 15;58(24):5812–5817. [PubMed] [Google Scholar]
  28. Rowse G. J., Tempero R. M., VanLith M. L., Hollingsworth M. A., Gendler S. J. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 1998 Jan 15;58(2):315–321. [PubMed] [Google Scholar]
  29. Ruiz P. J., Wolkowicz R., Waisman A., Hirschberg D. L., Carmi P., Erez N., Garren H., Herkel J., Karpuj M., Steinman L. Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nat Med. 1998 Jun;4(6):710–712. doi: 10.1038/nm0698-710. [DOI] [PubMed] [Google Scholar]
  30. Stewart L. M., Young S., Watson G., Mather S. J., Bates P. A., Band H. A., Wilkinson R. W., Ross E. L., Snary D. Humanisation and characterisation of PR1A3, a monoclonal antibody specific for cell-bound carcinoembryonic antigen. Cancer Immunol Immunother. 1999 Feb;47(6):299–306. doi: 10.1007/s002620050534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Taylor-Papadimitriou J., Peterson J. A., Arklie J., Burchell J., Ceriani R. L., Bodmer W. F. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer. 1981 Jul 15;28(1):17–21. doi: 10.1002/ijc.2910280104. [DOI] [PubMed] [Google Scholar]
  32. Tempero R. M., Rowse G. J., Gendler S. J., Hollingsworth M. A. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Int J Cancer. 1999 Feb 9;80(4):595–599. doi: 10.1002/(sici)1097-0215(19990209)80:4<595::aid-ijc18>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  33. Verhoeyen M. E., Saunders J. A., Price M. R., Marugg J. D., Briggs S., Broderick E. L., Eida S. J., Mooren A. T., Badley R. A. Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody. Immunology. 1993 Mar;78(3):364–370. [PMC free article] [PubMed] [Google Scholar]
  34. Zhang K., Sikut R., Hansson G. C. A MUC1 mucin secreted from a colon carcinoma cell line inhibits target cell lysis by natural killer cells. Cell Immunol. 1997 Mar 15;176(2):158–165. doi: 10.1006/cimm.1997.1085. [DOI] [PubMed] [Google Scholar]
  35. von Mensdorff-Pouilly S., Gourevitch M. M., Kenemans P., Verstraeten A. A., Litvinov S. V., van Kamp G. J., Meijer S., Vermorken J., Hilgers J. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer. 1996 Jul;32A(8):1325–1331. doi: 10.1016/0959-8049(96)00048-2. [DOI] [PubMed] [Google Scholar]
  36. von Mensdorff-Pouilly S., Verstraeten A. A., Kenemans P., Snijdewint F. G., Kok A., Van Kamp G. J., Paul M. A., Van Diest P. J., Meijer S., Hilgers J. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol. 2000 Feb;18(3):574–583. doi: 10.1200/JCO.2000.18.3.574. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES